• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, August 5, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Insilico Medicine to present at the CogX Festival of AI and Emerging Technology

Bioengineer by Bioengineer
May 30, 2019
in Biology
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Insilico Medicine

Thursday, May 30, 2019 – Insilico Medicine, a biotech company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at the CogX Festival of AI and Emerging Technology in London, on June 10th.

The CogX Festival of AI and Emerging Technology brings together more than 100 most innovative, disruptive tech startups in the world, as well as the brightest and most influential AI and emerging technology leaders to understand and experience the technology landscape trends and get the latest governmental and academic opinions on the opportunities and challenges for applications of AI and emerging technology. The CogX Festival provides an ideal platform for partnering, establishing and strengthening relationships and ecosystems with AI and emerging technology leaders from across the globe.

“We are on the brink of a technological revolution in healthcare where data collected from all different sources will influence the way we cure diseases. This approach aims to master disease treatment and extend it’s branches into preventive and longevity based means. At Insilico, we are using AI as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, artificial intelligence helps more drugs to be discovered. We are thrilled to be able to share the results of our research at the CogX – an incredible artificial intelligence festival coming to London this June,” said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine.

“I am really fascinated by the opportunity to participate in the CogX Festival, the event that contributes to the development of the innovative technology industries. It is such a great chance to listen to, learn from, and engage in debates with the brightest minds from the industry, and academia, and I am looking forward to sharing my own perspective as a female researcher and a deep learning scientist,” said Polina Mamoshina, Senior Research Scientist at Insilico Medicine.

###

For further information, images or interviews, please contact:

Contact: Klug Gehilfe
[email protected]

Website: http://insilico.com/

Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.

About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8.

Website: http://insilico.com/

Media Contact
Klug Gehilfe
[email protected]

Original Source

http://cogx.co/

Tags: AgingBioinformaticsBiotechnologyGerontology
Share15Tweet9Share2ShareShareShare2

Related Posts

Aldehydes’ Prooxidative Effects in Oil-Water Emulsions

Aldehydes’ Prooxidative Effects in Oil-Water Emulsions

August 5, 2025
Novel Arsenate-Reducing Bacteria Aid Soil Remediation

Novel Arsenate-Reducing Bacteria Aid Soil Remediation

August 5, 2025

Soy Sauce Packaging Shapes Taste, Feelings, Preferences

August 5, 2025

New Calyptospora Species Causes Liver Disease in Bagre

August 5, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Neuropsychiatric Risks Linked to COVID-19 Revealed

    71 shares
    Share 28 Tweet 18
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    46 shares
    Share 18 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Accurate Sample Volume Key in Microplastic Monitoring

Global Cancer Mortality Trends in Youth, 1990–2021

Aldehydes’ Prooxidative Effects in Oil-Water Emulsions

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.